Neuropathology and Applied Neurobiology | 2021
Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics
Abstract
Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility of co‐ordinated real‐time centralised pathology review (CPR), encompassing molecular diagnostics and contemporary genomics (RNA‐seq/DNA methylation‐array).